Purpose: The International Federation of Gynecology and Obstetric (FIGO) stage is critical to guiding the treatments of ovarian cancer (OC). We tried to develop a model to predict the FIGO stage of OC through machine learning algorithms with patients' pretreatment clinical, positron emission tomography scan (PET/CT) metabolic, and radiomics features.
Methods: We enrolled OC patients who underwent PET/CT scans and divided them into two cohorts according to their FIGO stage. Then we manually delineated the volume of interest (VOI) and calculated PET metabolic features. Other PET/CT radiomics features were extracted by Python. We developed 11 prediction models to predict stages based on four groups of features and conducted three experiments to verify the meaning of PET/CT features. We also redesigned experiments to demonstrate the stage prediction performance in ovarian clear cell carcinoma (OCCC) and mucinous ovarian cancer (MCOC).
Results: 183 OC patients were enrolled in this study, and we obtained 137 features from four groups of data. The best model was an adaptive ensemble with an area under the curve (AUC) value of 0.819. Our proposed models presented the best result of 0.808 in terms of AUC in OCCC and MCOC patients' groups.
Conclusion: Through artificial intelligence (AI) algorithms, the PET/CT metabolic and radiomics features combined with clinical features could improve the accuracy of staging prediction.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11842498 | PMC |
http://dx.doi.org/10.1007/s00432-025-06134-9 | DOI Listing |
Int J Gen Med
March 2025
Medical Imaging Center, Xi'an People's Hospital (Xi'an Fourth Hospital), Xi'an, Shaanxi Province, People's Republic of China.
Background: Cervical cancer remains a major cause of mortality among women globally, with lymph node metastasis (LNM) being a critical determinant of patient prognosis.
Methods: In this study, MRI scans from 153 cervical cancer patients between January 2018 and January 2024 were analyzed. The patients were assigned to two groups: 103 in the training cohort; 49 in the validation cohort.
Cancer Med
March 2025
Department of Gynecology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Backgrounds: A growing number of systematic bioinformatics analyses were conducted to investigate the mechanism of interaction between long non-coding RNA (lncRNA) and endometrial carcinoma (EC) to predict the prognosis. However, there is no evidence-based evidence that abnormal lncRNA expression is strongly associated with the pathological characteristics and prognosis of EC patients. In this meta-analysis, we systematically evaluated the relationship between upregulated lncRNA expression levels and clinicopathological features, five-year survival rate, and progression-free survival (PFS).
View Article and Find Full Text PDFAm J Surg Pathol
March 2025
Department of Pathology, Brigham and Women's Hospital, Harvard Medical School.
Endometrial gastric (gastrointestinal)-type mucinous adenocarcinoma (EmGA) is rare and was introduced as a new entity in the latest World Health Organization (WHO) classification of female genital tumors. Herein, we report a detailed clinicopathologic, immunohistochemical, and molecular study of 27 EmGA, the largest published series to date. The cohort consisted of 27 patients (median age 69 y; range 42 to 87 years).
View Article and Find Full Text PDFArch Gynecol Obstet
March 2025
Department of Obstetrics and Gynecology, Hebei Medical University, Fourth Hospital, Jiankanglu 12, Shijiazhuang, 050011, China.
Purpose: Endometrial carcinoma (EC) represents the most prevalent malignancy of the female genital tract in the United States, with lymphovascular space invasion (LVSI) recognized as a critical prognostic factor that significantly influences disease outcomes. This review aims to elucidate the evolving understanding of LVSI in early-stage EC, highlighting its implications for stratification, quantification, and clinical management.
Methods: A systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.
Gynecol Oncol
March 2025
Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham & Women's Hospital, 75 Francis Street, Boston, MA 02115, United States of America. Electronic address:
Background: There are limited data around adjuvant radiotherapy following surgical management for patients with early-stage uterine carcinosarcoma (UCS). We compared outcomes for patients with early-stage UCS who underwent adjuvant chemotherapy (CT) and pelvic external beam radiotherapy (EBRT) vs. CT and vaginal brachytherapy (VBT) vs.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!